Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes

NCT05040971 on ClinicalTrials.gov · last registry update 2026-01-29

A small phase 3 — 207 participants, against a typical 424. The sponsor logged completion for 6 January 2023. Primary outcome, as filed: Change in Body Weight (Percentage [%]). semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 207
Started: 2021-09-06
Primary completion: 2023-01-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Body Weight (Percentage [%])

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.